$ORGS
Orgenesis Inc. Stock $orgs

$orgs Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000149315224014652 Filed on April 15, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$246.0K	$165.0K	$530.0K
YoY Change	-96.47%	-98.79%	-98.53%
Cost Of Revenue	$538.0K	$162.0K	$6.255M
YoY Change	-83.35%	-97.36%	-76.89%
Gross Profit	-$292.0K	$3.000K	-$5.725M
YoY Change	-107.8%	-99.96%	-163.9%
Gross Profit Margin	-118.7%	1.82%	-1080.19%
Selling, General & Admin	$2.061M	$2.092M	$35.13M
YoY Change	-38.24%	-69.37%	125.38%
% of Gross Profit		69733.33%
Research & Development	$1.489M	$3.093M	$10.62M
YoY Change	-57.78%	49.85%	15.86%
% of Gross Profit		103100.0%
Depreciation & Amortization	$706.0K	$190.0K	$1.560M
YoY Change	18.26%	-15.56%	46.2%
% of Gross Profit		6333.33%
Operating Expenses	$3.550M	$5.305M	$45.76M
YoY Change	-48.28%	-24.82%	193.52%
Operating Profit	-$4.250M	-$5.302M	-$53.64M
YoY Change	27.67%	-1321.66%	523.53%
Interest Expense	-$835.0K	-$761.0K	-$3.226M
YoY Change	28.46%	29.42%	-7.27%
% of Operating Profit
Other Income/Expense, Net	-$815.0K	-$2.000K	-$2.499M
YoY Change	24.43%	-101.2%	26.79%
Pretax Income	-$9.361M	-$6.764M	-$64.45M
YoY Change	162.21%	514.91%	438.84%
Income Tax	$5.000K	-$141.0K	$473.0K
% Of Pretax Income
Net Earnings	-$8.904M	-$6.623M	-$55.36M
YoY Change	115.75%	61.65%	271.82%
Net Earnings / Revenue	-3619.51%	-4013.94%	-10445.47%
Basic Earnings Per Share	$0.23		$1.91
Diluted Earnings Per Share	$0.23	-$0.22	$1.91
COMMON SHARES
Basic Shares Outstanding	34.34M shares	31.88M shares	29.01M shares
Diluted Shares Outstanding	38.86M shares		29.01M shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$77.00K	$837.0K	$837.0K
YoY Change	-57.22%	-84.24%	-84.24%
Cash & Equivalents	$77.00K	$837.0K	$837.0K
Short-Term Investments
Other Short-Term Assets	$2.031M	$2.659M	$2.659M
YoY Change	-62.02%	31.89%	31.89%
Inventory		$34.00K	$34.00K
Prepaid Expenses
Receivables	$240.0K	$88.00K	$88.00K
Other Receivables	$0.00	$458.0K	$458.0K
Total Short-Term Assets	$2.348M	$4.076M	$4.076M
YoY Change	-74.74%	-91.2%	-91.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$15.90M	$1.475M	$1.826M
YoY Change	1173.1%	-93.54%	-92.74%
Goodwill	$1.211M	$1.211M
YoY Change	-67.3%	-85.21%
Intangibles	$8.724M	$7.375M
YoY Change	13.58%	-23.92%
Long-Term Investments	$8.000K	$8.000K	$8.000K
YoY Change	-99.97%	-94.07%	-94.07%
Other Assets	$331.0K	$18.00K	$56.00K
YoY Change	-53.84%	-98.24%	-96.15%
Total Long-Term Assets	$28.23M	$10.48M	$10.48M
YoY Change	-37.92%	-76.52%	-76.52%
TOTAL ASSETS
Total Short-Term Assets	$2.348M	$4.076M	$4.076M
Total Long-Term Assets	$28.23M	$10.48M	$10.48M
Total Assets	$30.58M	$14.55M	$14.55M
YoY Change	-44.17%	-84.0%	-84.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.41M	$6.584M	$6.584M
YoY Change	238.8%	48.66%	48.66%
Accrued Expenses	$2.789M	$2.218M	$3.513M
YoY Change	24.79%	-13.96%	-29.46%
Deferred Revenue	$350.0K	$200.0K
YoY Change		185.71%
Short-Term Debt	$1.186M	$650.0K	$650.0K
YoY Change
Long-Term Debt Due	$1.993M	$2.688M	$2.688M
YoY Change	-15.62%	-41.1%	-41.1%
Total Short-Term Liabilities	$31.70M	$16.41M	$16.41M
YoY Change	149.39%	3.12%	3.12%
LONG-TERM LIABILITIES
Long-Term Debt	$8.059M	$18.97M	$18.97M
YoY Change	-54.84%	41.17%	41.17%
Other Long-Term Liabilities	$371.0K	$61.00K	$157.0K
YoY Change	518.33%	-77.49%	-93.19%
Total Long-Term Liabilities	$14.67M	$19.13M	$19.13M
YoY Change	-18.92%	21.49%	21.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$31.70M	$16.41M	$16.41M
Total Long-Term Liabilities	$14.67M	$19.13M	$19.13M
Total Liabilities	$46.37M	$35.54M	$35.54M
YoY Change	50.54%	12.26%	-43.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$195.3M	-$176.6M
YoY Change	50.22%	45.97%
Common Stock	$5.000K	$156.8M
YoY Change	-100.0%	4.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.266M	$1.266M
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	-$15.50M	-$20.98M	-$20.98M
YoY Change
Total Liabilities & Shareholders Equity	$30.58M	$14.55M	$14.55M
YoY Change	-44.17%	-84.0%	-84.0%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$8.904M	-$6.623M	-$55.36M
YoY Change	115.75%	61.65%	271.82%
Depreciation, Depletion And Amortization	$706.0K	$190.0K	$1.560M
YoY Change	18.26%	-15.56%	46.2%
Cash From Operating Activities	-$5.907M	-$497.0K	-$14.84M
YoY Change	-0.12%	-95.38%	-40.41%
INVESTING ACTIVITIES
Capital Expenditures	$1.000K	-$4.000K	$2.096M
YoY Change	-99.8%	-100.07%	-83.12%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$61.00K	-$1.611M
YoY Change	-100.0%	-95.04%	-6.17%
Cash From Investing Activities	-$1.000K	-$57.00K	-$3.707M
YoY Change	-99.93%	-99.15%	-73.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.511M	1.228M	$13.62M
YoY Change	33.26%	-93.7%	-65.59%
NET CHANGE
Cash From Operating Activities	-5.907M	-497.0K	-$14.84M
Cash From Investing Activities	-1.000K	-57.00K	-$3.707M
Cash From Financing Activities	6.511M	1.228M	$13.62M
Net Change In Cash	603.0K	674.0K	-$4.926M
YoY Change	-123.9%	-67.07%	-1003.85%
FREE CASH FLOW
Cash From Operating Activities	-$5.907M	-$497.0K	-$14.84M
Capital Expenditures	$1.000K	-$4.000K	$2.096M
Free Cash Flow	-$5.908M	-$493.0K	-$16.93M
YoY Change	-8.05%	-96.96%	-54.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	ORGS	Convertible Loan ConvertibleLoan		usd
CY2023Q4	ORGS	Loans To Associates LoansToAssociates		usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet		usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings		usd
CY2023Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent		usd
CY2023Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount		usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest		usd
CY2022	ORGS	Impairment Of Investment ImpairmentOfInvestment		usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
CY2022	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount		usd
CY2022	ORGS	Credit Loss On Convertible Loan Receivable CreditLossOnConvertibleLoanReceivable		usd
CY2022	ORGS	Release Of Translation Adjustment Due To Deconsolidation Of Octomera ReleaseOfTranslationAdjustmentDueToDeconsolidationOfOctomera		usd
CY2023	ORGS	Stock Issued During Period Value Issuance Of Shares Due To Exercise Of Warrants StockIssuedDuringPeriodValueIssuanceOfSharesDueToExerciseOfWarrants		usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2022	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount		usd
CY2022	ORGS	Impairment Of Investment ImpairmentOfInvestment		usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
CY2022	ORGS	Increase Decrease In Related Parties Net IncreaseDecreaseInRelatedPartiesNet		usd
CY2023	ORGS	Proceeds From Repayment Of Convertible Loan To Related Party Partners ProceedsFromRepaymentOfConvertibleLoanToRelatedPartyPartners		usd
CY2022	ORGS	Decrease In Loan To Associate Entities DecreaseInLoanToAssociateEntities		usd
CY2023	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable		usd
CY2023	ORGS	Repayment Of Loan Granted RepaymentOfLoanGranted		usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2022	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates		usd
CY2023	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition		usd
CY2022	ORGS	Impact To Cash Resulting From Deconsolidation ImpactToCashResultingFromDeconsolidation		usd
CY2023	ORGS	Proceeds From Increase In Cash From Business Combinations ProceedsFromIncreaseInCashFromBusinessCombinations		usd
CY2022	us-gaap	Proceeds From Repayments Of Bank Overdrafts ProceedsFromRepaymentsOfBankOverdrafts		usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability		usd
CY2023	ORGS	Loan Conversion For Redeemable Noncontrolling Interest LoanConversionForRedeemableNoncontrollingInterest		usd
CY2023	ORGS	Issuance Of Common Stocks In Connection With Acquisition IssuanceOfCommonStocksInConnectionWithAcquisition		usd
CY2022	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments		usd
CY2023	ORGS	Payment To Acquire Loan To Granted Associations PaymentToAcquireLoanToGrantedAssociations		usd
CY2022	ORGS	Decrease In Loan To Associate Entities DecreaseInLoanToAssociateEntities		usd
CY2023	ORGS	Equity Method Investments To Acquire Business Combination EquityMethodInvestmentsToAcquireBusinessCombination		usd
CY2023	us-gaap	Proceeds From Collection Of Retained Interest In Securitized Receivables Categorized As Available For Sale ProceedsFromCollectionOfRetainedInterestInSecuritizedReceivablesCategorizedAsAvailableForSale		usd
CY2022	us-gaap	Proceeds From Collection Of Retained Interest In Securitized Receivables Categorized As Available For Sale ProceedsFromCollectionOfRetainedInterestInSecuritizedReceivablesCategorizedAsAvailableForSale		usd
CY2023	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2022	ORGS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability		usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree		usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree		usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour		usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour		usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive		usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive		usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive		usd
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount		usd
CY2023Q4	ORGS	Deferred Tax Assets Loans DeferredTaxAssetsLoans		usd
CY2022Q4	ORGS	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets Bad Debt Allowance DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssetsBadDebtAllowance		usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2022	ORGS	Deferred Tax Assets Valuation Allowance Deconsolidation DeferredTaxAssetsValuationAllowanceDeconsolidation		usd
CY2022	ORGS	Accounts Receivable Deconsolidation AccountsReceivableDeconsolidation		usd
CY2023	ORGS	Accounts Receivable Acquisition Of Tlabs AccountsReceivableAcquisitionOfTlabs		usd
CY2022	ORGS	Accounts Receivable Allowances For Doubtful Accounts AccountsReceivableAllowancesForDoubtfulAccounts		usd
CY2022	ORGS	Contract With Customer Liability Deconsolidation ContractWithCustomerLiabilityDeconsolidation		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	35033921	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34338782	shares
CY2023	dei	Auditor Firm AuditorFirmId	1309
CY2023	dei	Auditor Name AuditorName	Kesselman & Kesselman
CY2023	dei	Auditor Location AuditorLocation	Haifa, Israel
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	837000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5311000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	642000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1058000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	88000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	36183000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2017000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	958000	usd
CY2022Q4	ORGS	Convertible Loan ConvertibleLoan	2688000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	34000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	120000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	4076000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	46318000	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	38000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	331000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	8000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	39000	usd
CY2022Q4	ORGS	Loans To Associates LoansToAssociates	96000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1475000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22834000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7375000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9694000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	351000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2304000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1211000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	8187000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	103000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1022000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	10476000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	44610000	usd
CY2023Q4	us-gaap	Assets Assets	14552000	usd
CY2022Q4	us-gaap	Assets Assets	90928000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2218000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2648000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	740000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	289000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1079000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1860000	usd
CY2023Q4	ORGS	Advance Payments On Account Of Grant AdvancePaymentsOnAccountOfGrant	2180000	usd
CY2022Q4	ORGS	Advance Payments On Account Of Grant AdvancePaymentsOnAccountOfGrant	1578000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	650000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	18000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	60000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	216000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	542000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2670000	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	4504000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16407000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15910000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	96000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1728000	usd
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	18967000	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	13343000	usd
CY2022Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	163000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	95000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	61000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	415000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	19128000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	15744000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	35535000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	31654000	usd
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	30203000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	145833334	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	145833334	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32163630	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25832322	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31877063	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25545755	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	156837000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	150355000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	65000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-270000	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	286567	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	286567	shares
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1266000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1266000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-176622000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-121261000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-20983000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	27561000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	1510000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-20983000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	29071000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14552000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	90928000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	530000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	36025000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	6255000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	5133000	usd
CY2023	us-gaap	Gross Profit GrossProfit	-5725000	usd
CY2022	us-gaap	Gross Profit GrossProfit	30892000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10623000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21933000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	721000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	911000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	24367000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	35134000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15589000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1508000	usd
CY2023	ORGS	Impairment Of Investment ImpairmentOfInvestment	699000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	1061000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-10110000	usd
CY2023	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	-5343000	usd
CY2023	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	4000	usd
CY2023	ORGS	Credit Loss On Convertible Loan Receivable CreditLossOnConvertibleLoanReceivable	2688000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-283000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-52000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2499000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1971000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-64445000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11960000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	473000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	209000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-64918000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-12169000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-9557000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	2720000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-55361000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14889000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.91
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.91
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.59
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.59
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29007869	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29007869	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25096284	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25096284	shares
CY2023	us-gaap	Profit Loss ProfitLoss	-64918000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-12169000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	49000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	477000	usd
CY2023	ORGS	Release Of Translation Adjustment Due To Deconsolidation Of Octomera ReleaseOfTranslationAdjustmentDueToDeconsolidationOfOctomera	-384000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest	64583000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest	12646000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	9557000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	-2720000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55026000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15366000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	29071000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	415000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	48000	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	5283000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	449000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	287000	usd
CY2023	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	8430000	usd
CY2023	us-gaap	Noncontrolling Interest Increase From Sale Of Parent Equity Interest NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest	9406000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-55560000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-20983000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	38631000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	38631000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	916000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	66000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	950000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2175000	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	100000	usd
CY2022	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	1353000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-12646000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	29071000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	29071000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-64918000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-12169000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	463000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	982000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	170000	usd
CY2023	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	-5343000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-734000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1508000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1560000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1978000	usd
CY2023	ORGS	Credit Loss On Convertible Loan Receivable CreditLossOnConvertibleLoanReceivable	2688000	usd
CY2023	ORGS	Impairment Of Investment ImpairmentOfInvestment	699000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	1061000	usd
CY2023	ORGS	Increase Decrease In Effect Of Exchange Differences On Intercompany Balances IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances	227000	usd
CY2022	ORGS	Increase Decrease In Effect Of Exchange Differences On Intercompany Balances IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances	502000	usd
CY2023	ORGS	Net Changes In Operating Leases NetChangesInOperatingLeases	50000	usd
CY2022	ORGS	Net Changes In Operating Leases NetChangesInOperatingLeases	61000	usd
CY2023	ORGS	Interest Expense Accrued On Loans And Convertible Loans InterestExpenseAccruedOnLoansAndConvertibleLoans	-1508000	usd
CY2022	ORGS	Interest Expense Accrued On Loans And Convertible Loans InterestExpenseAccruedOnLoansAndConvertibleLoans	-1372000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-283000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-52000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-30060000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	21051000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-432000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-391000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	389000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-13000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-26000	usd
CY2023	ORGS	Increase Decrease In Related Parties Net IncreaseDecreaseInRelatedPartiesNet	439000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5516000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1321000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1013000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2302000	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	411000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-216000	usd
CY2023	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-9000	usd
CY2022	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	103000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14837000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24924000	usd
CY2022	ORGS	Proceeds From Repayment Of Convertible Loan To Related Party Partners ProceedsFromRepaymentOfConvertibleLoanToRelatedPartyPartners	538000	usd
CY2023	ORGS	Decrease In Loan To Associate Entities DecreaseInLoanToAssociateEntities	55000	usd
CY2022	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	4131000	usd
CY2022	ORGS	Repayment Of Loan Granted RepaymentOfLoanGranted	782000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	246000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2096000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12416000	usd
CY2023	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	660000	usd
CY2022	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	702000	usd
CY2023	ORGS	Impact To Cash Resulting From Deconsolidation ImpactToCashResultingFromDeconsolidation	973000	usd
CY2022	ORGS	Proceeds From Increase In Cash From Business Combinations ProceedsFromIncreaseInCashFromBusinessCombinations	-160000	usd
CY2023	ORGS	Repayment Of Investment In Longterm Deposits RepaymentOfInvestmentInLongtermDeposits	33000	usd
CY2022	ORGS	Repayment Of Investment In Longterm Deposits RepaymentOfInvestmentInLongtermDeposits	14000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3707000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14133000	usd
CY2023	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	5283000	usd
CY2022	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	2181000	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5735000	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	19150000	usd
CY2023	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	5000000	usd
CY2022	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	20000000	usd
CY2023	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	3000000	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	2300000	usd
CY2023	us-gaap	Repayments Of Debt RepaymentsOfDebt	35000	usd
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	46000	usd
CY2023	us-gaap	Proceeds From Repayments Of Bank Overdrafts ProceedsFromRepaymentsOfBankOverdrafts	635000	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1396000	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	803000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13618000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	39578000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4926000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	521000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	36000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-126000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6369000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5974000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1479000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6369000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	136000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	752000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	432000	usd
CY2023	ORGS	Increase Decrease In Accounts Payable Related To Purchase Of Property Plant And Equipment IncreaseDecreaseInAccountsPayableRelatedToPurchaseOfPropertyPlantAndEquipment	14000	usd
CY2022	ORGS	Increase Decrease In Accounts Payable Related To Purchase Of Property Plant And Equipment IncreaseDecreaseInAccountsPayableRelatedToPurchaseOfPropertyPlantAndEquipment	-383000	usd
CY2022	ORGS	Loan Conversion For Redeemable Noncontrolling Interest LoanConversionForRedeemableNoncontrollingInterest	10203000	usd
CY2022	ORGS	Issuance Of Common Stocks In Connection With Acquisition IssuanceOfCommonStocksInConnectionWithAcquisition	100000	usd
CY2023	ORGS	Extinguishment In Connection With Convertible Loan Restructuring ExtinguishmentInConnectionWithConvertibleLoanRestructuring	287000	usd
CY2022	ORGS	Extinguishment In Connection With Convertible Loan Restructuring ExtinguishmentInConnectionWithConvertibleLoanRestructuring	226000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	785000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	458000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-176622000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14837000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zmdfxtc7kgCf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>a.</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zEfbkg4IppC4">Use of Estimates in the Preparation of Financial Statements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Company’s consolidated financial statements in conformity with U.S. GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity, the amount of revenues and expenses, determination of loss on deconsolidation, valuation of investments, goodwill impairment, and assessment of credit losses. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	ORGS	Impairment Charges Of Other Investment ImpairmentChargesOfOtherInvestment	699	usd
CY2023	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	greater than 50% likely of being realized upon ultimate settlement
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_z09Sohq93U2j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>r.</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zYqR30TImTaf">Concentration of Credit Risk</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents, <span style="background-color: white">bank deposits</span> and certain receivables. The Company held these instruments with highly rated financial institutions and the Company has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant credit risk on these instruments apart of accounts receivable. The Company performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for doubtful accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s accounts receivable accounting policy until December 31, 2022, prior to the adoption of the new Current Expected Credit Losses (“CECL”) standard, created bad debts when objective evidence existed of inability to collect all sums owed it under the original terms of the debit balances. Material customer difficulties, the probability of their going bankrupt or undergoing economic reorganization and insolvency, material delays in payments and other objective considerations by management that indicate expected risk of payment were all considered indicative of reduced debtor balance value. Effective January 1, 2023, the Company adopted the new CECL standard. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The Company maintains the allowance for estimated losses resulting from the inability of the Company’s customers to make required payments. The Company considers historical collection experience for each of its customers and when revenue and accounts receivable are recorded. The Company also recognizes estimated expected credit losses over the life of the accounts receivables. The estimate of expected credit losses considers not only historical information, but also current and future economic conditions and events.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	When determining lease classification, the Company’s approach in assessing two of the mentioned criteria is: (i) generally 75% or more of the remaining economic life of the underlying asset is a major part of the remaining economic life of that underlying asset; and (ii) generally 90% or more of the fair value of the underlying asset comprises substantially all of the fair value of the underlying asset
CY2023Q4	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	0	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	8000	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	39000	usd
CY2023Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.08	pure
CY2022Q4	ORGS	Equity Method Investments And Loans To Associates EquityMethodInvestmentsAndLoansToAssociates	135000	usd
CY2021Q4	ORGS	Equity Method Investments And Loans To Associates EquityMethodInvestmentsAndLoansToAssociates	584000	usd
CY2023	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	660000	usd
CY2022	ORGS	Payment To Acquire Loan To Granted Associations PaymentToAcquireLoanToGrantedAssociations	4131000	usd
CY2023	ORGS	Decrease In Loan To Associate Entities DecreaseInLoanToAssociateEntities	55000	usd
CY2022	ORGS	Equity Method Investments To Acquire Business Combination EquityMethodInvestmentsToAcquireBusinessCombination	-3156000	usd
CY2022	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	161000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-734000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1508000	usd
CY2023	ORGS	Equity Method Investment Exchange Rate Difference EquityMethodInvestmentExchangeRateDifference	2000	usd
CY2022	ORGS	Equity Method Investment Exchange Rate Difference EquityMethodInvestmentExchangeRateDifference	-77000	usd
CY2023Q4	ORGS	Equity Method Investments And Loans To Associates EquityMethodInvestmentsAndLoansToAssociates	8000	usd
CY2022Q4	ORGS	Equity Method Investments And Loans To Associates EquityMethodInvestmentsAndLoansToAssociates	135000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	530000	usd
CY2023	ORGS	Cost Of Revenue Excluding Depreciation And Amortization Expenses CostOfRevenueExcludingDepreciationAndAmortizationExpenses	5774000	usd
CY2023	ORGS	Gross Profit Excluding Depreciation And Amortization Expenses GrossProfitExcludingDepreciationAndAmortizationExpenses	-5244000	usd
CY2023	ORGS	Research And Development Expense Excluding Depreciation And Amortization Expenses ResearchAndDevelopmentExpenseExcludingDepreciationAndAmortizationExpenses	10311000	usd
CY2023	ORGS	Operating Expenses Excluding Depreciation And Amortization Expenses OperatingExpensesExcludingDepreciationAndAmortizationExpenses	-35088000	usd
CY2023	ORGS	Impairment Of Investment ImpairmentOfInvestment	699000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-734000	usd
CY2023	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	-5343000	usd
CY2023	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	4000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1560000	usd
CY2023	ORGS	Credit Loss On Convertible Loan Receivable CreditLossOnConvertibleLoanReceivable	2688000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-283000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2499000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-64445000	usd
CY2022	us-gaap	Revenues Revenues	34741000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	36025000	usd
CY2022	ORGS	Cost Of Revenue Excluding Depreciation And Amortization Expenses CostOfRevenueExcludingDepreciationAndAmortizationExpenses	5492000	usd
CY2022	ORGS	Gross Profit Excluding Depreciation And Amortization Expenses GrossProfitExcludingDepreciationAndAmortizationExpenses	30533000	usd
CY2022	ORGS	Cost Of Development Services And Research And Development Expenses CostOfDevelopmentServicesAndResearchAndDevelopmentExpenses	21268000	usd
CY2022	ORGS	Operating Expenses Excluding Depreciation And Amortization Expenses OperatingExpensesExcludingDepreciationAndAmortizationExpenses	-15540000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1061000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1508000	usd
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	173000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1978000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-52000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1971000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11960000	usd
CY2023Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	942000	usd
CY2023Q4	ORGS	Transaction Fees TransactionFees	158000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	5381460	shares
CY2022Q4	ORGS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	4.41
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	3042521	shares
CY2021Q4	ORGS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	6.09
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	2891245	shares
CY2023	ORGS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice	1.46
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	2978575	shares
CY2022	ORGS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice	3.16
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	973684	shares
CY2023	ORGS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice	1.90
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	1456979	shares
CY2023	ORGS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice	5.63
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	639636	shares
CY2022	ORGS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice	6.58
CY2023Q4	ORGS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber	5842042	shares
CY2023Q4	ORGS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding And Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice	3.06
CY2022Q4	ORGS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber	5381460	shares
CY2022Q4	ORGS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding And Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice	4.41
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2050000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26786000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	575000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3952000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1475000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22834000	usd
CY2023	us-gaap	Depreciation Depreciation	839000	usd
CY2022	us-gaap	Depreciation Depreciation	1067000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1475000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22834000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1475000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22834000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	8403000	usd
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-216000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	8187000	usd
CY2023	ORGS	Goodwill Deconsolidation GoodwillDeconsolidation	-6815000	usd
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-161000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1211000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	9340000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	12420000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1965000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2726000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7375000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9694000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	721000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	911000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	612000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2450000	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	2300000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	351000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2304000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	89000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	222000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	65000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	68000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	24000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	154000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	216000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	542000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	18000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	330000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	22000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	18000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	60000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	96000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1728000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	95000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y1M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y8M12D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y2M12D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.075	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080	pure
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.020	pure
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.064	pure
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	561000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	546000	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	46000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	43000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	5000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	7000	usd
CY2023	ORGS	Finance Lease Cost FinanceLeaseCost	51000	usd
CY2022	ORGS	Finance Lease Cost FinanceLeaseCost	50000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	573000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	559000	usd
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	44000	usd
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	43000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	752000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	432000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	136000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	231000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	18000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	99000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	4000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	312000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	22000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	216000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	18000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	96000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4000	usd
CY2023	ORGS	Schedule Of Rightofuse Assets By Geographical Location ScheduleOfRightofuseAssetsByGeographicalLocation	<p id="xdx_893_ecustom--ScheduleOfRightofuseAssetsByGeographicalLocation_zx1TsXQYWu05" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease right-of-use assets by geographical location were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_z9ETyPUWh7hd" style="display: none">SCHEDULE OF RIGHT-OF-USE ASSETS BY GEOGRAPHICAL LOCATION</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.5in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">(in thousands)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%">Greece</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--GR_z4rcSAgqLp93" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating lease right-of-use assets"><span style="-sec-ix-hidden: xdx2ixbrl1862">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20221231__srt--StatementGeographicalAxis__country--GR_zGa69UkCV6Ga" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating lease right-of-use assets">1,368</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Korea</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--KR_zyZXGp5TKUZe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating lease right-of-use assets"><span style="-sec-ix-hidden: xdx2ixbrl1866">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20221231__srt--StatementGeographicalAxis__country--KR_zRstBd5UnCg7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating lease right-of-use assets">218</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Israel</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--IL_zBJvgTgJJI9i" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating lease right-of-use assets">292</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20221231__srt--StatementGeographicalAxis__country--IL_zlnSlw0sucMd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating lease right-of-use assets">580</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">U.S.</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--US_ztpxaqdHvBAk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating lease right-of-use assets">59</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20221231__srt--StatementGeographicalAxis__country--US_z6jEH8sFvKb2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating lease right-of-use assets">138</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20231231_zUlzLb1ZFL3e" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating lease right-of-use assets">351</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20221231_zAtWkuiVCUpl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating lease right-of-use assets">2,304</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	351000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2304000	usd
CY2023	ORGS	Repayments Of Grant Percentage Of Gross Sales RepaymentsOfGrantPercentageOfGrossSales	0.05	pure
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	184000	usd
CY2023	us-gaap	Fee Income FeeIncome	215000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-55361000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14889000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29007869	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29007869	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25096284	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25096284	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.91
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.91
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.59
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.59
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	510017	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.012
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	50000	usd
CY2023	ORGS	Employee Service Sharebased Compensation Nonvested Total Compensation Cost Not Yet Recognized And Period For Recognition In Years EmployeeServiceSharebasedCompensationNonvestedTotalCompensationCostNotYetRecognizedAndPeriodForRecognitionInYears	P2Y3M3D
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	36000000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	22000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12331000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10387000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3932000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1893000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1563000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1616000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	70000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	191000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	26000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	55000	usd
CY2023Q4	ORGS	Deferred Tax Assets Leases Asset DeferredTaxAssetsLeasesAsset	66000	usd
CY2022Q4	ORGS	Deferred Tax Assets Leases Asset DeferredTaxAssetsLeasesAsset	191000	usd
CY2023Q4	ORGS	Deferred Tax Liabilities Lease Liability DeferredTaxLiabilitiesLeaseLiability	67000	usd
CY2022Q4	ORGS	Deferred Tax Liabilities Lease Liability DeferredTaxLiabilitiesLeaseLiability	132000	usd
CY2022Q4	ORGS	Deferred Tax Assets Loans DeferredTaxAssetsLoans	50000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	8627000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	2582000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1629000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	2252000	usd
CY2023Q4	ORGS	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets Bad Debt Allowance DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssetsBadDebtAllowance	575000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1088000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	385000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	26530000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14856000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	26530000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14753000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	103000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14753000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12805000	usd
CY2023	ORGS	Deferred Tax Assets Valuation Allowance Deconsolidation DeferredTaxAssetsValuationAllowanceDeconsolidation	1252000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-13029000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-1948000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	26530000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14753000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	530000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	36025000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	36183000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15245000	usd
CY2023	ORGS	Accounts Receivable Deconsolidation AccountsReceivableDeconsolidation	5985000	usd
CY2022	ORGS	Accounts Receivable Acquisition Of Tlabs AccountsReceivableAcquisitionOfTlabs	-1339000	usd
CY2023	ORGS	Accounts Receivable Additions AccountsReceivableAdditions	560000	usd
CY2022	ORGS	Accounts Receivable Additions AccountsReceivableAdditions	35103000	usd
CY2023	ORGS	Accounts Receivable Collections AccountsReceivableCollections	-6230000	usd
CY2022	ORGS	Accounts Receivable Collections AccountsReceivableCollections	-12728000	usd
CY2023	ORGS	Accounts Receivable Allowances For Doubtful Accounts AccountsReceivableAllowancesForDoubtfulAccounts	-24388000	usd
CY2023	ORGS	Exchange Rate Differences Of Accounts Receivable ExchangeRateDifferencesOfAccountsReceivable	-52000	usd
CY2022	ORGS	Exchange Rate Differences Of Accounts Receivable ExchangeRateDifferencesOfAccountsReceivable	-98000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	88000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	36183000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	70000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	59000	usd
CY2023	ORGS	Contract With Customer Liability Deconsolidation ContractWithCustomerLiabilityDeconsolidation	106000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	236000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	11000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	200000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	70000	usd
CY2023	ORGS	Interest Expense On Convertible Loans InterestExpenseOnConvertibleLoans	2167000	usd
CY2022	ORGS	Interest Expense On Convertible Loans InterestExpenseOnConvertibleLoans	1824000	usd
CY2023	ORGS	Foreign Currency Transactions Gain Loss Realized ForeignCurrencyTransactionsGainLossRealized	325000	usd
CY2022	ORGS	Foreign Currency Transactions Gain Loss Realized ForeignCurrencyTransactionsGainLossRealized	145000	usd
CY2023	us-gaap	Other Income OtherIncome	-7000	usd
CY2022	us-gaap	Other Income OtherIncome	-2000	usd
CY2023	ORGS	Total Financial Expenses TotalFinancialExpenses	2499000	usd
CY2022	ORGS	Total Financial Expenses TotalFinancialExpenses	1971000	usd
CY2023	us-gaap	Loss Contingency Actions Taken By Plaintiff LossContingencyActionsTakenByPlaintiff	In the Complaint, the plaintiffs are seeking that the Court issue a declaratory remedy whereby the defendants are required to pay royalties to the plaintiffs at the rate of 7% of the sales and 24% of any and all revenues in consideration for sublicenses related to any product, service or process that contain know-how and technology of Sheba and any and all know-how and technology either developed or supervised by Prof. Ferber in the field of cell therapy, including in the category of the point-of-care platform and any and all services and products in relation to the defendants’ CDMO activity
CY2022Q1	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	10000000
CY2023Q3	us-gaap	Royalty Guarantees Commitments Amount RoyaltyGuaranteesCommitmentsAmount	896000	usd
CY2023Q4	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	40140000
CY2023Q4	us-gaap	Shares Issued SharesIssued	11869600	shares

Files In Submission

Name	View Source	Status
0001493152-24-014652-index-headers.html	Edgar Link	pending
0001493152-24-014652-index.html	Edgar Link	pending
0001493152-24-014652.txt	Edgar Link	pending
0001493152-24-014652-xbrl.zip	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex23-1_001.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
form10-k_003.jpg	Edgar Link	pending
form10-k_004.jpg	Edgar Link	pending
form10-k_005.jpg	Edgar Link	pending
form10-k_006.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
orgs-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
orgs-20231231_def.xml	Edgar Link	unprocessable
orgs-20231231_lab.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
orgs-20231231_cal.xml	Edgar Link	unprocessable
orgs-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ORGS
Orgenesis Inc. Stock $orgs

2024 Q2 Form 10-K Financial Statement

#000149315224014652 Filed on April 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORGS Orgenesis Inc. Stock $orgs

2024 Q2 Form 10-K Financial Statement

#000149315224014652 Filed on April 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORGS
Orgenesis Inc. Stock $orgs